Polycythemia vera

Common Name(s)

Polycythemia vera

Polycythemia vera (PV) is a condition characterized by an increased number of red blood cells in the bloodstream. Affected people may also have excess white blood cells and platelets. These extra cells cause the blood to be thicker than normal, increasing the risk for blood clots that can block blood flow in arteries and veins. People with PV have an increased risk of deep vein thrombosis which can cause a pulmonary embolism, heart attack, and stroke. Most cases of PV are not inherited and are acquired during a person's lifetime. In rare cases, the risk for PV runs in families and may be inherited in an autosomal dominant manner. The condition has been associated with mutations in the JAK2 and TET2 genes.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Polycythemia vera" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Polycythemia vera" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

http://www.mpdsupport.org

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

http://www.mpnresearchfoundation.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Polycythemia vera" returned 310 free, full-text research articles on human participants. First 3 results:

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
 

Author(s): Alessandro M Vannucchi

Journal: N. Engl. J. Med.. 2015 Apr;372(17):1670-1.

 

Last Updated: 23 Apr 2015

Go To URL
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
 

Author(s): Alessandro M Vannucchi, Jean Jacques Kiladjian, Martin Griesshammer, Tamas Masszi, Simon Durrant, Francesco Passamonti, Claire N Harrison, Fabrizio Pane, Pierre Zachee, Ruben Mesa, Shui He, Mark M Jones, William Garrett, Jingjin Li, Ulrich Pirron, Dany Habr, Srdan Verstovsek

Journal: N. Engl. J. Med.. 2015 Jan;372(5):426-35.

 

Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with polycythemia vera in a phase 2 study. We conducted a phase 3 open-label study to evaluate the efficacy and safety of ruxolitinib versus standard therapy in patients with polycythemia ...

Last Updated: 29 Jan 2015

Go To URL
Nongenetic stochastic expansion of JAK2V617F-homozygous subclones in polycythemia vera?
 

Author(s): Anna L Godfrey, Jyoti Nangalia, E Joanna Baxter, Charles E Massie, David G Kent, Elli Papaemmanuil, Peter J Campbell, Anthony R Green

Journal: Blood. 2014 Nov;124(22):3332-4.

 

Last Updated: 21 Nov 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Polycythemia vera" returned 20 free, full-text review articles on human participants. First 3 results:

Current and future treatment options for polycythemia vera.
 

Author(s): Martin Griesshammer, Heinz Gisslinger, Ruben Mesa

Journal: Ann. Hematol.. 2015 Jun;94(6):901-10.

 

Patients with polycythemia vera (PV), a myeloproliferative neoplasm characterized by an elevated red blood cell mass, are at high risk of vascular and thrombotic complications and have reduced quality of life due to a substantial symptom burden that includes pruritus, fatigue, constitutional ...

Last Updated: 6 May 2015

Go To URL
β-Thalassemia and Polycythemia vera: targeting chronic stress erythropoiesis.
 

Author(s): Bart J Crielaard, Stefano Rivella

Journal: Int. J. Biochem. Cell Biol.. 2014 Jun;51():89-92.

 

β-Thalassemia and Polycythemia vera are genetic disorders which affect the synthesis of red blood cells, also referred to as erythropoiesis. Although essentially different in clinical presentation - patients with β-thalassemia have an impairment in β-globin synthesis leading to ...

Last Updated: 26 May 2014

Go To URL
Neutrophilic dermatosis of the dorsal hands in a patient with polycythemia vera.
 

Author(s): Pedro de Vasconcelos, Luís Soares-Almeida, Paulo Filipe

Journal: Acta Dermatovenerol Alp Pannonica Adriat. 2013 ;22(2):53-4.

 

Last Updated: 9 Jul 2013

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Last Updated: 11 May 2015

Go to URL
AOP2014 in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.
 

Status: Recruiting

Condition Summary: Polycythemia Vera

 

Last Updated: 12 Jun 2015

Go to URL

Last Updated: 14 May 2015

Go to URL